XOMA Royalty (XOMA) Cash from Investing Activities (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Cash from Investing Activities came in at $6.6 million in Q1 2026, up 197.89% year-on-year from $2.2 million in Q1 2025, and down 66.13% quarter-over-quarter from $19.3 million in Q4 2025.
XOMA Royalty (XOMA) Cash from Investing Activities (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Cash from Investing Activities across 16 years of filings, most recently posting $6.6 million for Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at $6.6 million, up 197.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $64.1 million (up 331.47% YoY), and the FY2025 annual result was $50.9 million, up 280.07% from the prior year.
- Cash from Investing Activities came in at $6.6 million for Q1 2026 at XOMA Royalty, down from $19.3 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $58.2 million in Q3 2025 to a low of -$36.4 million in Q4 2024.
- The 5-year median for Cash from Investing Activities is -$2.2 million (2022), against an average of $515437.5.
- Across the five-year window, Cash from Investing Activities jumped 21030.77% in 2023 and sank 761.06% in 2024, its largest moves.
- XOMA Royalty's Cash from Investing Activities stood at -$15.2 million in 2022, then soared by 136.14% to $5.5 million in 2023, then tumbled by 761.06% to -$36.4 million in 2024, then surged by 153.11% to $19.3 million in 2025, then tumbled by 66.13% to $6.6 million in 2026.
- The last three Cash from Investing Activities figures came in at $6.6 million (Q1 2026), $19.3 million (Q4 2025), and $58.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 579,519.10 |
| 10 | XOMA Royalty | 5.48 Mn | -60.60 Mn | - | 6.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.55 Mn |
| Mar 31, 2026 | 6.55 Mn |
| Dec 31, 2025 | 19.35 Mn |
| Dec 31, 2025 | 19.35 Mn |
| Sep 30, 2025 | 58.21 Mn |
| Sep 30, 2025 | 58.21 Mn |
| Jun 30, 2025 | -19.98 Mn |
| Jun 30, 2025 | -19.98 Mn |
| Mar 31, 2025 | -6.69 Mn |
| Mar 31, 2025 | -6.69 Mn |
| Dec 31, 2024 | -36.43 Mn |
| Dec 31, 2024 | -36.43 Mn |
| Sep 30, 2024 | 9.52 Mn |
| Sep 30, 2024 | 9.52 Mn |
| Jun 30, 2024 | 5.90 Mn |
| Jun 30, 2024 | 5.90 Mn |
| Mar 31, 2024 | -7.25 Mn |
| Mar 31, 2024 | -7.25 Mn |
| Dec 31, 2023 | 5.51 Mn |
| Dec 31, 2023 | 5.51 Mn |